Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia (Q34404506)

2 August 2017

1 reference

title

Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia (English)

1 reference

2 August 2017

0 references

1 reference

1 reference

Atweh GF

1

1 reference

PubMed ID

11605172

2 August 2017

Loukopoulos D

series ordinal

2

1 reference

2 August 2017

1 October 2001

1 reference

2 August 2017

Seminars in Hematology

1 reference

2 August 2017

38

1 reference

2 August 2017

4

1 reference

2 August 2017

367-373

1 reference

Successful use of hydroxyurea in beta-thalassemia major

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Sickle cell anemia and trait in a population of southern India

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Hematological responses to hydroxyurea therapy in multitransfused thalassemic children

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Hydroxyurea for the treatment of sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Hydroxyurea therapy in paraparesis and cauda equina syndrome due to extramedullary haematopoiesis in thalassaemia: improvement of clinical and haematological parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Pharmacologic treatment of thalassemia intermedia with hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Hydroxyurea and hemin affect both the transcriptional and post-transcriptional mechanisms of some globin genes in human adult erythroid cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Augmentation of Fetal-Hemoglobin Production in Anemic Monkeys by Hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Hydroxyurea therapy in thalassemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Levels of fetal hemoglobin necessary for treatment of sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Treatment of thalassaemia major with phenylbutyrate and hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Delay in the fetal globin switch in infants of diabetic mothers

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Mortality in sickle cell disease. Life expectancy and risk factors for early death.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Pain in sickle cell disease. Rates and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

The role of recombinant human erythropoietin in the treatment of thalassemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Clinical and hematological response to hydroxyurea in a patient with Hb Lepore/beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Hematologic Responses of Patients with Sickle Cell Disease to Treatment with Hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Erythroid progenitor proliferation is stimulated by phenoxyacetic and phenylalkyl acids

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

The significance of the paucity of sickle cells in newborn Negro infants

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990031-9

7 January 2021

10.1016/S0037-1963(01)90031-9

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11605172